Discovery - University of Dundee - Online Publications

Library & Learning Centre

Interventions for the treatment of oral cavity and oropharyngeal cancer

Standard

Interventions for the treatment of oral cavity and oropharyngeal cancer : chemotherapy. / Furness, Susan; Glenny, Anne-Marie; Worthington, Helen V.; Pavitt, Sue; Oliver, Richard; Clarkson, Jan E.; Macluskey, Michaelina; Chan, Kelvin K. W.; Conway, David I.; CSROC Expert Panel.

In: Cochrane Database of Systematic Reviews, No. 9, CD006386, 2010, p. -.

Research output: Contribution to journalScientific review

Harvard

Furness, S, Glenny, A-M, Worthington, HV, Pavitt, S, Oliver, R, Clarkson, JE, Macluskey, M, Chan, KKW, Conway, DI & CSROC Expert Panel 2010, 'Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy' Cochrane Database of Systematic Reviews, no. 9, CD006386, pp. -.

APA

Furness, S., Glenny, A-M., Worthington, H. V., Pavitt, S., Oliver, R., Clarkson, J. E., Macluskey, M., Chan, K. K. W., Conway, D. I., & CSROC Expert Panel (2010). Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. Cochrane Database of Systematic Reviews, (9), -[CD006386]doi: 10.1002/14651858.CD006386.pub2

Vancouver

Furness S, Glenny A-M, Worthington HV, Pavitt S, Oliver R, Clarkson JE et al. Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. Cochrane Database of Systematic Reviews. 2010;(9):-. CD006386.

Author

Furness, Susan; Glenny, Anne-Marie; Worthington, Helen V.; Pavitt, Sue; Oliver, Richard; Clarkson, Jan E.; Macluskey, Michaelina; Chan, Kelvin K. W.; Conway, David I.; CSROC Expert Panel / Interventions for the treatment of oral cavity and oropharyngeal cancer : chemotherapy.

In: Cochrane Database of Systematic Reviews, No. 9, CD006386, 2010, p. -.

Research output: Contribution to journalScientific review

Bibtex - Download

@article{be755e57dcb94790b908c09fe3f23aa3,
title = "Interventions for the treatment of oral cavity and oropharyngeal cancer",
author = "Susan Furness and Anne-Marie Glenny and Worthington, {Helen V.} and Sue Pavitt and Richard Oliver and Clarkson, {Jan E.} and Michaelina Macluskey and Chan, {Kelvin K. W.} and Conway, {David I.} and {CSROC Expert Panel}",
year = "2010",
number = "9",
pages = "--",
journal = "Cochrane Database of Systematic Reviews",
issn = "1469-493X",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Interventions for the treatment of oral cavity and oropharyngeal cancer

T2 - chemotherapy

A1 - Furness,Susan

A1 - Glenny,Anne-Marie

A1 - Worthington,Helen V.

A1 - Pavitt,Sue

A1 - Oliver,Richard

A1 - Clarkson,Jan E.

A1 - Macluskey,Michaelina

A1 - Chan,Kelvin K. W.

A1 - Conway,David I.

A1 - CSROC Expert Panel

AU - Furness,Susan

AU - Glenny,Anne-Marie

AU - Worthington,Helen V.

AU - Pavitt,Sue

AU - Oliver,Richard

AU - Clarkson,Jan E.

AU - Macluskey,Michaelina

AU - Chan,Kelvin K. W.

AU - Conway,David I.

AU - CSROC Expert Panel

PY - 2010

Y1 - 2010

N2 - <p>Background</p> <p>Oral cavity and oropharyngeal cancers are frequently described as part of a group of oral cancers or head and neck cancer. Treatment of oral cavity cancer is generally surgery followed by radiotherapy, whereas oropharyngeal cancers, which are more likely to be advanced at the time of diagnosis, are managed with radiotherapy or chemoradiation. Surgery for oral cancers can be disfiguring and both surgery and radiotherapy have significant functional side effects, notably impaired ability to eat, drink and talk. The development of new chemotherapy agents, new combinations of agents and changes in the relative timing of surgery, radiotherapy, and chemotherapy treatments may potentially bring about increases in both survival and quality of life for this group of patients.</p> <p>Objectives</p> <p>To determine whether chemotherapy, in addition to radiotherapy and/or surgery for oral cavity and oropharyngeal cancer results in improved survival, disease free survival, progression free survival, locoregional control and reduced recurrence of disease. To determine which regimen and time of administration (induction, concomitant or adjuvant) is associated with better outcomes.</p> <p>Search strategy</p> <p>Electronic searches of the Cochrane Oral Health Group's Trials Register, CENTRAL, MEDLINE, EMBASE, AMED were undertaken on 28th July 2010. Reference lists of recent reviews and included studies were also searched to identify further trials.</p> <p>Selection criteria</p> <p>Randomised controlled trials where more than 50% of participants had primary tumours in the oral cavity or oropharynx, and which compared the addition of chemotherapy to other treatments such as radiotherapy and/or surgery, or compared two or more chemotherapy regimens or modes of administration, were included.</p> <p>Data collection and analysis</p> <p>Trials which met the inclusion criteria were assessed for risk of bias using six domains: sequence generation, allocation concealment, blinding, completeness of outcome data, selective reporting and other possible sources of bias. Data were extracted using a specially designed form and entered into the characteristics of included studies table and the analysis sections of the review. The proportion of participants in each trial with oral cavity and oropharyngeal cancers are recorded in Additional Table 1.</p> <p>Main results</p> <p>There was no statistically significant improvement in overall survival associated with induction chemotherapy compared to locoregional treatment alone in 25 trials (hazard ratio (HR) of mortality 0.92, 95% confidence interval (CI) 0.84 to 1.00). Post-surgery adjuvant chemotherapy was associated with improved overall survival compared to surgery +/- radiotherapy alone in 10 trials (HR of mortality 0.88, 95% CI 0.79 to 0.99), and there was an additional benefit of adjuvant concomitant chemoradiotherapy compared to radiotherapy in 4 of these trials (HR of mortality 0.84, 95% CI 0.72 to 0.98). Concomitant chemoradiotherapy resulted in improved survival compared to radiotherapy alone in patients whose tumours were considered unresectable in 25 trials (HR of mortality 0.79, 95% CI 0.74 to 0.84). However, the additional toxicity attributable to chemotherapy in the combined regimens remains unquantified.</p> <p>Authors' conclusions Chemotherapy, in addition to radiotherapy and surgery, is associated with improved overall survival in patients with oral cavity and oropharyngeal cancers. Induction chemotherapy is associated with a 9% increase in survival and adjuvant concomitant chemoradiotherapy is associated with a 16% increase in overall survival following surgery. In patients with unresectable tumours, concomitant chemoradiotherapy showed a 22% benefit in overall survival compared with radiotherapy alone.</p> <p><strong>This review is published as a Cochrane Review in the Cochrane Database of Systematic Reviews 2010, Issue 9. Cochrane Reviews are regularly updated as new evidence emerges and in response to comments and criticisms, and the Cochrane Database of Systematic Reviews should be consulted for the most recent version of the Review.</strong></p>

AB - <p>Background</p> <p>Oral cavity and oropharyngeal cancers are frequently described as part of a group of oral cancers or head and neck cancer. Treatment of oral cavity cancer is generally surgery followed by radiotherapy, whereas oropharyngeal cancers, which are more likely to be advanced at the time of diagnosis, are managed with radiotherapy or chemoradiation. Surgery for oral cancers can be disfiguring and both surgery and radiotherapy have significant functional side effects, notably impaired ability to eat, drink and talk. The development of new chemotherapy agents, new combinations of agents and changes in the relative timing of surgery, radiotherapy, and chemotherapy treatments may potentially bring about increases in both survival and quality of life for this group of patients.</p> <p>Objectives</p> <p>To determine whether chemotherapy, in addition to radiotherapy and/or surgery for oral cavity and oropharyngeal cancer results in improved survival, disease free survival, progression free survival, locoregional control and reduced recurrence of disease. To determine which regimen and time of administration (induction, concomitant or adjuvant) is associated with better outcomes.</p> <p>Search strategy</p> <p>Electronic searches of the Cochrane Oral Health Group's Trials Register, CENTRAL, MEDLINE, EMBASE, AMED were undertaken on 28th July 2010. Reference lists of recent reviews and included studies were also searched to identify further trials.</p> <p>Selection criteria</p> <p>Randomised controlled trials where more than 50% of participants had primary tumours in the oral cavity or oropharynx, and which compared the addition of chemotherapy to other treatments such as radiotherapy and/or surgery, or compared two or more chemotherapy regimens or modes of administration, were included.</p> <p>Data collection and analysis</p> <p>Trials which met the inclusion criteria were assessed for risk of bias using six domains: sequence generation, allocation concealment, blinding, completeness of outcome data, selective reporting and other possible sources of bias. Data were extracted using a specially designed form and entered into the characteristics of included studies table and the analysis sections of the review. The proportion of participants in each trial with oral cavity and oropharyngeal cancers are recorded in Additional Table 1.</p> <p>Main results</p> <p>There was no statistically significant improvement in overall survival associated with induction chemotherapy compared to locoregional treatment alone in 25 trials (hazard ratio (HR) of mortality 0.92, 95% confidence interval (CI) 0.84 to 1.00). Post-surgery adjuvant chemotherapy was associated with improved overall survival compared to surgery +/- radiotherapy alone in 10 trials (HR of mortality 0.88, 95% CI 0.79 to 0.99), and there was an additional benefit of adjuvant concomitant chemoradiotherapy compared to radiotherapy in 4 of these trials (HR of mortality 0.84, 95% CI 0.72 to 0.98). Concomitant chemoradiotherapy resulted in improved survival compared to radiotherapy alone in patients whose tumours were considered unresectable in 25 trials (HR of mortality 0.79, 95% CI 0.74 to 0.84). However, the additional toxicity attributable to chemotherapy in the combined regimens remains unquantified.</p> <p>Authors' conclusions Chemotherapy, in addition to radiotherapy and surgery, is associated with improved overall survival in patients with oral cavity and oropharyngeal cancers. Induction chemotherapy is associated with a 9% increase in survival and adjuvant concomitant chemoradiotherapy is associated with a 16% increase in overall survival following surgery. In patients with unresectable tumours, concomitant chemoradiotherapy showed a 22% benefit in overall survival compared with radiotherapy alone.</p> <p><strong>This review is published as a Cochrane Review in the Cochrane Database of Systematic Reviews 2010, Issue 9. Cochrane Reviews are regularly updated as new evidence emerges and in response to comments and criticisms, and the Cochrane Database of Systematic Reviews should be consulted for the most recent version of the Review.</strong></p>

KW - SQUAMOUS-CELL CARCINOMA

KW - LOCALLY ADVANCED HEAD

KW - RANDOMIZED PHASE-II

KW - CISPLATIN PLUS 5-FLUOROURACIL

KW - TRIAL COMPARING RADIOTHERAPY

KW - COOPERATIVE-ONCOLOGY-GROUP

KW - STAGE-IV HEAD

KW - ACCELERATED HYPERFRACTIONATED RADIOTHERAPY

KW - COMBINED POSTOPERATIVE RADIOTHERAPY

KW - UNRESECTABLE PHARYNGEAL CARCINOMA

U2 - 10.1002/14651858.CD006386.pub2

DO - 10.1002/14651858.CD006386.pub2

M1 - Scientific review

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

SN - 1469-493X

IS - 9

SP - -

ER -

Documents

Library & Learning Centre

Contact | Accessibility | Policy